These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 23371904)

  • 1. Progress in the reprogramming of somatic cells.
    Ma T; Xie M; Laurent T; Ding S
    Circ Res; 2013 Feb; 112(3):562-74. PubMed ID: 23371904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological Reprogramming of Somatic Cells for Regenerative Medicine.
    Xie M; Tang S; Li K; Ding S
    Acc Chem Res; 2017 May; 50(5):1202-1211. PubMed ID: 28453285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemically Induced Reprogramming of Somatic Cells to Pluripotent Stem Cells and Neural Cells.
    Biswas D; Jiang P
    Int J Mol Sci; 2016 Feb; 17(2):226. PubMed ID: 26861316
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of small molecules on cell reprogramming.
    Baranek M; Belter A; Naskręt-Barciszewska MZ; Stobiecki M; Markiewicz WT; Barciszewski J
    Mol Biosyst; 2017 Jan; 13(2):277-313. PubMed ID: 27918060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small molecules for reprogramming and transdifferentiation.
    Qin H; Zhao A; Fu X
    Cell Mol Life Sci; 2017 Oct; 74(19):3553-3575. PubMed ID: 28698932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RNA-based tools for nuclear reprogramming and lineage-conversion: towards clinical applications.
    Bernal JA
    J Cardiovasc Transl Res; 2013 Dec; 6(6):956-68. PubMed ID: 23852582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reprogram or reboot: small molecule approaches for the production of induced pluripotent stem cells and direct cell reprogramming.
    Jung DW; Kim WH; Williams DR
    ACS Chem Biol; 2014 Jan; 9(1):80-95. PubMed ID: 24245936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic Control of Reprogramming and Transdifferentiation by Histone Modifications.
    Qin H; Zhao A; Zhang C; Fu X
    Stem Cell Rev Rep; 2016 Dec; 12(6):708-720. PubMed ID: 27623868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular Reprogramming Using Protein and Cell-Penetrating Peptides.
    Seo BJ; Hong YJ; Do JT
    Int J Mol Sci; 2017 Mar; 18(3):. PubMed ID: 28273812
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced pluripotent stem cells: fundamentals and applications of the reprogramming process and its ramifications on regenerative medicine.
    Walia B; Satija N; Tripathi RP; Gangenahalli GU
    Stem Cell Rev Rep; 2012 Mar; 8(1):100-15. PubMed ID: 21671061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemical reprogramming and transdifferentiation.
    Xie X; Fu Y; Liu J
    Curr Opin Genet Dev; 2017 Oct; 46():104-113. PubMed ID: 28755566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the roadmaps to induced pluripotency.
    Liu K; Song Y; Yu H; Zhao T
    Cell Death Dis; 2014 May; 5(5):e1232. PubMed ID: 24832604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular reprogramming: a small molecule perspective.
    Nie B; Wang H; Laurent T; Ding S
    Curr Opin Cell Biol; 2012 Dec; 24(6):784-92. PubMed ID: 22959962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transient acquisition of pluripotency during somatic cell transdifferentiation with iPSC reprogramming factors.
    Maza I; Caspi I; Zviran A; Chomsky E; Rais Y; Viukov S; Geula S; Buenrostro JD; Weinberger L; Krupalnik V; Hanna S; Zerbib M; Dutton JR; Greenleaf WJ; Massarwa R; Novershtern N; Hanna JH
    Nat Biotechnol; 2015 Jul; 33(7):769-74. PubMed ID: 26098448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of Reprogramming Factors Alters the Trajectory of Somatic Lineage Conversion.
    Velychko S; Kang K; Kim SM; Kwak TH; Kim KP; Park C; Hong K; Chung C; Hyun JK; MacCarthy CM; Wu G; Schöler HR; Han DW
    Cell Rep; 2019 Apr; 27(1):30-39.e4. PubMed ID: 30943410
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic cell reprogramming as a tool for neurodegenerative diseases.
    Ebrahimi A; Keske E; Mehdipour A; Ebrahimi-Kalan A; Ghorbani M
    Biomed Pharmacother; 2019 Apr; 112():108663. PubMed ID: 30970509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced pluripotency and direct reprogramming: a new window for treatment of neurodegenerative diseases.
    Li R; Bai Y; Liu T; Wang X; Wu Q
    Protein Cell; 2013 Jun; 4(6):415-24. PubMed ID: 23686735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Engineering cell fate: Spotlight on cell-activation and signaling-directed lineage conversion.
    Ebrahimi B
    Tissue Cell; 2016 Oct; 48(5):475-87. PubMed ID: 27514850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual expression of reprogramming factors affects the transcriptional program and epigenetic signatures of induced pluripotent stem cells.
    Sommer CA; Christodoulou C; Gianotti-Sommer A; Shen SS; Sailaja BS; Hezroni H; Spira A; Meshorer E; Kotton DN; Mostoslavsky G
    PLoS One; 2012; 7(12):e51711. PubMed ID: 23272148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NKX3-1 is required for induced pluripotent stem cell reprogramming and can replace OCT4 in mouse and human iPSC induction.
    Mai T; Markov GJ; Brady JJ; Palla A; Zeng H; Sebastiano V; Blau HM
    Nat Cell Biol; 2018 Aug; 20(8):900-908. PubMed ID: 30013107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.